SOFOSBUVIR, 400mg, tab.


Valid Article

Former Code(s): DORAZNL0334 DORAZBE0058 - Pangenotypic direct-acting antiviral combinations
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
The order of this product needs to be justified and is only acceptable under certain conditions.
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

    This combination does not exist.

    Add article to list


    Add Kit To Wishlist


    SOFOSBUVIR, 400mg, tab.

    Non-standard item as the FDC of daclastavir 60mg / sofosbuvir 400mg (DORADASO64T) is now available

    Reference List

    Trade Name


    Therapeutic Action

    Nucleotide analogue NS5B polymerase inhibitor


    Chronic hepatitis C virus (HCV) infection, in combination with other antiviral medicines

    Instructions for use

    To be used in combination with daclatasvir, with or without ribavirin

    The fixed-dose combination (FDC) of DACLASTAVIR 60mg / SOFOSBUVIR 400mg is the preferred option


    Below 25°C